Proprietary platform for neurological drug development
HQ Country
San Carlos, United States
Employees
11-50
Founded
2019
HQ State/Province
California
Funding Category
Series B
HQ Full Address
930 Brittan Avenue, San Carlos, California 94070, United States
Product Features & Capabilities
CU-13001 oral small molecule for Parkinson's disease
M3D platform for druggable target identification
Miro1 biomarker for neurological disease detection
Other Considerations
Supported by Stanford University and major foundations; Funded by the Michael J. Fox Foundation; Collaborations with Parkinson's UK and the National Institute on Aging